Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax

Total 29 results found. Search for [ GVK Biosciences ]

Results 1 to 21 of 29
Nevin John
Delhi, July 19, 2017
N. Chandrasekaran is doing his best to restore normalcy at the Tata Group after the acrimonious exit of Cyrus Mistry. But his problems are many.

March 25, 2017
The decision, announced by the European Medicines Agency (EMA) on its website, is the latest blow for India's drug-testing industry, which has run into a series of problems with international regulators in recent years.

Mumbai, April 18, 2016
The European Medicines Agency (EMA) is investigating the medicines after Germany reported its findings to the EMA and urged it to take action in a report that was posted on the EMA website.

New Delhi, November 27, 2015
\"Proposals of ScaleneWorks People Solutions LLP, GVK Biosciences and Singapore-based GMS Pharma got cleared. They are worth Rs 160 crore,\" a finance ministry official said.

New Delhi, October 6, 2015
Prime Minister Narendra Modi asked the German Chancellor to use her influence in EU to remove the impediments for resumption of FTA talks with the 28-member bloc.

Manoj Kumar
New Delhi, August 17, 2015
Prime Minister Narendra Modi's office wrote to the EU Trade Commissioner to intervene when the ban on around 700 pharmaceutical products was formalised in May, but there was no response, so the government cancelled an August 28 meeting to discuss restarting talks on the free trade accord that stalled in 2012.

New Delhi, August 9, 2015
The European Union has been India's largest trading partner and the two-way trade is likely to swell significantly if the countries could firm up the long-pending Free Trade Agreement, officially called the Broad based Investment and Trade Agreement
August 8, 2015
Quick takes on major events that happened recently.

E Kumar Sharma
August 6, 2015
It is still not clear who is severely impacted by the ban. Because if the impact was huge on any company, it would have by now informed the stock exchanges.

New Delhi, August 5, 2015
The India-EU trade talks, formally known as the Broad- based Trade and Investment Agreement (BTIA), remain stuck as both sides are not satisfied with each other's offers.

E Kumar Sharma
July 28, 2015
Following the completion of the acquisition, a company statement said Teva \"is expected to have pro forma sales of approximately $26 billion and EBITDA of approximately $9.5 billion in 2016, including an estimated $11 billion in sales outside of the United States.\"

E Kumar Sharma
July 28, 2015
European Union banned marketing of 700 generic drugs due to alleged manipulation of clinical trials conducted at GVK Biosciences.

E Kumar Sharma
July 27, 2015
If the government were to have its way, all domestic manufacturers will need to incorporate bar coding and Unique Identification Number on every pack of medicine, so as to enable effective tracking of the products right from its inception stage to the delivery point.

E Kumar Sharma
July 26, 2015
\"GVK BIO is disappointed with the fact that even after multiple appeals, a deeper scientific dialogue was not undertaken\", the company said in a statement mailed to Business Today.

Zeba Siddiqui
Mumbai, April 15, 2015
India may go to WTO if the European Union does not reconsider its decision to suspend the sale of about 700 generic drugs that were approved based on clinical trials by GVK Biosciences, the firm said.

K Mammen Mathew
Berlin, January 24, 2015
The move is being seen as the EU's determination to maintain high ethical and medical standards for approval of medicines.

K Mammen Mathew
Berlin, December 10, 2014
The German drug regulator also suspended the marketing authorisation given to the drugs concerned based on the data of clinical trials supplied by GVK Biosciences.

Hyderabad, December 8, 2014
Replying to a query, company's CEO said it would cost about Rs 30 lakh to redo the studies, which the company is willing to bear on behalf of the clients.

E Kumar Sharma
December 6, 2014
\"We are clearly disappointed by the outcome and do feel it raises questions on the future viability of this business,\" Manni Kantipudi, CEO of GVK Biosciences told.

E. Kumar Sharma
Delhi, August 2, 2014
GVK group chalks out an ambitious plan to retire debt in the holding companies of its core infrastructure business.

PAGES 1 OF 2  12